SRPT vs. CLS
SRPT (Sarepta Therapeutics, Inc.) and CLS (Celestica Inc.) are both stocks. SRPT operates in Biotechnology (Healthcare), while CLS operates in Electronic Components (Technology). Over the past 10 years, SRPT returned -0.70%/yr vs 43.13%/yr for CLS. At a 0.20 correlation, their price movements are largely independent.
Performance
SRPT vs. CLS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SRPT achieves a -19.80% return, which is significantly lower than CLS's 18.81% return. Over the past 10 years, SRPT has underperformed CLS with an annualized return of -0.70%, while CLS has yielded a comparatively higher 43.13% annualized return.
SRPT
- 1D
- -2.21%
- 1M
- 2.74%
- YTD
- -19.80%
- 6M
- -21.55%
- 1Y
- -8.53%
- 3Y*
- -46.72%
- 5Y*
- -26.36%
- 10Y*
- -0.70%
CLS
- 1D
- -6.80%
- 1M
- -4.40%
- YTD
- 18.81%
- 6M
- 15.73%
- 1Y
- 157.59%
- 3Y*
- 191.08%
- 5Y*
- 113.59%
- 10Y*
- 43.13%
SRPT vs. CLS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SRPT Sarepta Therapeutics, Inc. | -19.80% | -82.30% | 26.09% | -25.58% | 43.90% | -47.18% | 32.12% | 18.24% | 96.14% | 102.84% |
CLS Celestica Inc. | 18.81% | 220.27% | 215.23% | 159.80% | 1.26% | 37.92% | -2.42% | -5.70% | -16.32% | -11.56% |
Correlation
The correlation between SRPT and CLS is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.19 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.16 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.19 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Jun 30, 1998 | 0.20 |
Fundamentals
SRPT:
$2.10B
CLS:
$40.63B
SRPT:
$0.60
CLS:
$8.28
SRPT:
28.76
CLS:
42.39
SRPT:
0.86
CLS:
2.95
SRPT:
1.40
CLS:
19.37
SRPT:
$2.18B
CLS:
$13.81B
SRPT:
$751.34M
CLS:
$1.60B
SRPT:
$107.91M
CLS:
$1.32B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SRPT vs. CLS — Risk / Return Rank
SRPT
CLS
SRPT vs. CLS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Sarepta Therapeutics, Inc. (SRPT) and Celestica Inc. (CLS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SRPT | CLS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.26 | ||
| Sortino ratioReturn per unit of downside risk | -1.90 | ||
| Omega ratioGain probability vs. loss probability | 1.08 | 1.32 | -0.24 |
| Calmar ratioReturn relative to maximum drawdown | -0.19 | 5.42 | -5.61 |
| Martin ratioReturn relative to average drawdown | -0.41 | 12.78 | -13.19 |
Loading charts...
Drawdowns
SRPT vs. CLS - Drawdown Comparison
The maximum SRPT drawdown since its inception was -98.17%, roughly equal to the maximum CLS drawdown of -96.93%. Use the drawdown chart below to compare losses from any high point for SRPT and CLS.
Loading charts...
Drawdown Indicators
| SRPT | CLS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.17% | -96.93% | -1.24% |
Max Drawdown (1Y)Largest decline over 1 year | -45.70% | -29.24% | -16.46% |
Max Drawdown (3Y)Largest decline over 3 years | -92.72% | -53.96% | -38.76% |
Max Drawdown (5Y)Largest decline over 5 years | -92.72% | -53.96% | -38.76% |
Max Drawdown (10Y)Largest decline over 10 years | -93.33% | -80.60% | -12.73% |
Current DrawdownCurrent decline from peak | -90.34% | -25.66% | -64.68% |
Average DrawdownAverage peak-to-trough decline | -68.19% | -73.27% | +5.08% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.63% | 12.38% | +8.25% |
Volatility
SRPT vs. CLS - Volatility Comparison
The current volatility for Sarepta Therapeutics, Inc. (SRPT) is 15.99%, while Celestica Inc. (CLS) has a volatility of 27.86%. This indicates that SRPT experiences smaller price fluctuations and is considered to be less risky than CLS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SRPT | CLS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 15.99% | 27.86% | -11.87% |
Volatility (6M)Calculated over the trailing 6-month period | 52.64% | 54.05% | -1.41% |
Volatility (1Y)Calculated over the trailing 1-year period | 94.13% | 73.04% | +21.09% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 69.84% | 57.84% | +12.00% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 70.36% | 50.05% | +20.31% |
Dividends
SRPT vs. CLS - Dividend Comparison
Neither SRPT nor CLS has paid dividends to shareholders.
Financials
SRPT vs. CLS - Financials Comparison
This section allows you to compare key financial metrics between Sarepta Therapeutics, Inc. and Celestica Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SRPT vs. CLS - Profitability Comparison
SRPT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Sarepta Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 730.80M. Therefore, the gross margin over that period was 0.0%.
CLS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a gross profit of 437.20M and revenue of 4.05B. Therefore, the gross margin over that period was 10.8%.
SRPT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Sarepta Therapeutics, Inc. reported an operating income of 358.43M and revenue of 730.80M, resulting in an operating margin of 49.1%.
CLS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported an operating income of 272.10M and revenue of 4.05B, resulting in an operating margin of 6.7%.
SRPT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Sarepta Therapeutics, Inc. reported a net income of 330.96M and revenue of 730.80M, resulting in a net margin of 45.3%.
CLS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a net income of 212.30M and revenue of 4.05B, resulting in a net margin of 5.3%.
Frequently Asked Questions
SRPT and CLS have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CLS has higher volatility (27.86%) compared to SRPT (15.99%). In terms of maximum drawdown, SRPT dropped -98.17% vs CLS's -96.93%.
CLS currently has the higher Sharpe Ratio (2.17 vs -0.09), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SRPT and CLS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer